1092: Baseline Aclf Grade and Treatment Response to Terlipressin in Patients With Hepatorenal Syndrome

Abstract

Hepatorenal syndrome type 1 (HRS) is an advanced form of decompensated cirrhosis characterized by rapid-onset kidney failure. Acute-on-chronic liver failure (ACLF)-defined as acute liver decompensation followed by organ failure (OF)-is a common and concerning condition for many hospitalized patients (pts) with HRS. Terlipressin (TERLI), a vasopressin analogue, is an effective treatment for acute kidney injury in pts with HRS, however ACLF severity may impact treatment response. Pooled data from 3 North American-centric, Phase III, randomized, placebo (PBO)controlled studies were analyzed to determine if baseline ACLF grade affected the treatment response to TERLI in pts with HRS. METHODS:A retrospective analysis using pooled data from the OT-0401, REVERSE, and CONFIRM Phase III studies was performed to compare the incidence of HRS reversal by baseline ACLF grade in pts treated with TERLI + albumin vs PBO + albumin for up to 14 days. Severity of ACLF was graded according to the number of OFs (ACLF grade 0-1, grade 2, and grade 3). The incidence of HRS reversal was defined as at least 1 serum creatinine value of ≤1.5 mg/dL while on treatment.